Different Assays for Her-2/neu Evaluation in Breast Cancer

Tommasi, Stefania; Paradiso, Angelo; Serio, G; Barletta, A.; Mangia, A.; Giannella, C.; Lena, M. De

doi:10.1177/030089169207800208

Cited by 3 publications

(3 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A good agreement was also found between the expression evaluated by western blotting technique and IHC [4,9,10], although Tommasi et al found a higher percentage of altered samples when overexpression was measured by western blotting. Concordances in prognostic indications were also found [9].…”

Section: Introductionmentioning

confidence: 80%

“…On the other hand, biochemical methods show complementary characteristics, providing quantitative determination of the protein in a significant amount of the tissue. The studies that evaluated the concordances between these methods showed satisfactory results [4,9,10]. However, the number of these studies is limited, and they have only partially investigated the results in relation to other biopathological characteristics of the tumour.…”

Section: Discussionmentioning

confidence: 99%

“…In terms of clinical use, it seems moreover that prognostic power of one methodology could differ from another. Some studies have evaluated both gene amplification and protein expression, and have found a good correlation [3][4][5][6][7][8]. The discordances dealt especially with the presence of cancer specimens with overexpression and without amplification.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Determination of ErbB2 protein in breast cancer tissues by different methods. Relationships with other biological parameters

Piffanelli

Dittadi²,

Catozzi

et al. 1996

Breast Cancer Res Tr

View full text Add to dashboard Cite

Four different methods to measure in parallel the erbB2 protein expression (p185neu) were evaluated in order to: a) compare two enzyme immunoassays with the immunohistochemical assays (IHC) and western blotting (WB) and b) extrapolate eventual relationships between erbB2 and biological parameters. Tissue samples from 248 patients with primary breast cancer were consecutively assayed. We used two different cut-off levels for WB, ELISA, and EIA, defined as follows: 1) the highest level of expression of non malignant tissue was chosen as the discriminant threshold between 'low' and 'elevated' samples: 2) the elevated group was further subdivided into two subgroups: 'intermediate' and 'high', according to their median value. According to the first cut-off, the results were considered 'elevated' in about 52% of cases with the three biochemical methods, while using the second cut-off the percentage lowered to about 26%. Considering this cut-off, the concordance rates between the paired biochemical methods ranged between: 78.4% (WB vs EIA), 93% (ELISA vs EIA), and 82.6% (ELISA vs WB). The comparison between biochemical and immunohistochemical methods gave these concordance rates: 82% (WB vs IHC), 90.5% (ELISA vs IHC), and 85.5% (EIA vs. IHC). According to the first cut off level, 27.5% of tumor samples showed IHC detectable p185 levels, in agreement with other immunohistochemical studies. The relationship between high erbB2 and estrogen and progesterone receptors showed an inverse association. No relationship was found between erbB2 and axillary lymph node positivity or tumor size. In short, the results of the four methods seem generally well correlated; nevertheless, it appears that different methodological approaches of measuring p185neu are not completely equivalent, and there is a need for an authoritative standardization and quality control for clinical applications.

show abstract

Section: Introductionmentioning

confidence: 80%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Determination of ErbB2 protein in breast cancer tissues by different methods. Relationships with other biological parameters

Piffanelli

Dittadi²,

Catozzi

et al. 1996

Breast Cancer Res Tr

View full text Add to dashboard Cite

show abstract

Biomarkers in Benign Breast Disease: Risk Factors for Breast Cancer

Allred¹,

Hilsenbeck²

1998

JNCI: Journal of the National Cancer Institute

View full text Add to dashboard Cite

Variations in c-erbB-2 Proto-oncogene Status in Breast Cancer Tumors as Detected by Two Different cDNA Probes

Pegoraro

Lanning²,

Rom³

1996

Diagnostic Molecular Pathology

View full text Add to dashboard Cite

We examined 232 breast carcinomas for c-erbB-2 amplification by Southern analysis using two different cDNA probes. Using these same probes, 95 of these tumors were also examined for mRNA expression by Northern analysis. Amplification was detected in 20 and 17% of the tumors with the probes pHER 2 and pCER 204, respectively, but only 10% showed amplification with both probes. A significantly higher incidence (p < 0.01) of mRNA overexpression was detected with the pHER 2 probe (34%) compared with the pCER 204 probe (16%), with only 11% of tumors demonstrating overexpression with both probes. A total of 10 tumors (11%) exhibited amplification as well as overexpression with pHER 2, whereas significantly fewer (3%) manifested both abnormalities with the larger pCER 204 probe (p < 0.05). Amplification of c-erbB-2, as detected with the pHER 2 probe but not with the pCER 204 probe, was significantly associated with the absence of both estrogen and progesterone receptors (p < 0.05 and p < 0.01, respectively). No relationship was found with other clinical prognostic indicators, such as nodal involvement and metastases. As determined by either probe, overexpression was not associated with prognostic indicators. There was no significant difference in the c-erbB-2 status of tumors from different racial groups.

show abstract

Different Assays for Her-2/neu Evaluation in Breast Cancer

Cited by 3 publications

References 13 publications

Determination of ErbB2 protein in breast cancer tissues by different methods. Relationships with other biological parameters

Determination of ErbB2 protein in breast cancer tissues by different methods. Relationships with other biological parameters

Biomarkers in Benign Breast Disease: Risk Factors for Breast Cancer

Variations in c-erbB-2 Proto-oncogene Status in Breast Cancer Tumors as Detected by Two Different cDNA Probes

Contact Info

Product

Resources

About